Baseline Radiologic Features As Predictors of Efficacy in Patients with Pancreatic Neuroendocrine Tumors with Liver Metastases Receiving Surufatinib.
Jianwei Zhang,Haibin Zhu,Lin Shen,Jie Li,Xiaoyan Zhang,Chunmei Bai,Zhiwei Zhou,Xianrui Yu,Zhiping Li,Enxiao Li,Xianglin Yuan,Wenhui Lou,Yihebali Chi,Nong Xu,Yongmei Yin,Yuxian Bai,Tao Zhang,Dianrong Xiu,Jia Chen,Shukui Qin,Xiuwen Wang,Yujie Yang,Haoyun Shi,Xian Luo,Songhua Fan,Weiguo Su,Ming Lu,Jianming Xu
DOI: https://doi.org/10.21147/j.issn.1000-9604.2023.05.09
2023-01-01
Abstract:Objective:Currently, pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases (PNELM) receiving surufatinib treatment was unsatisfying. Our objective was to examine the association between radiological characteristics and efficacy/prognosis.Methods:We enrolled patients with liver metastases in the phase III, SANET-p trial (NCT02589821) and obtained contrast-enhanced computed tomography (CECT) images. Qualitative and quantitative parameters including hepatic tumor margins, lesion volumes, enhancement pattern, localization types, and enhancement ratios were evaluated. The progression-free survival (PFS) and hazard ratio (HR) were calculated using Cox's proportional hazard model. Efficacy was analyzed by logistic-regression models.Results:Among 152 patients who had baseline CECT assessments and were included in this analysis, the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters. In the multivariable analysis of patients receiving surufatinib (N=100), those with higher arterial phase standardized enhancement ratio-peri-lesion (ASER-peri) exhibited longer PFS [HR=0.039; 95% confidence interval (95% CI): 0.003-0.483; P=0.012]. Furthermore, patients with a high enhancement pattern experienced an improvement in the objective response ratio [31.3% vs. 14.7%, odds ratio (OR)=3.488; 95% CI: 1.024-11.875; P=0.046], and well-defined tumor margins were associated with a higher disease control rate (DCR) (89.3% vs. 68.2%, OR=4.535; 95% CI: 1.285-16.011; P=0.019) compared to poorly-defined margins.Conclusions:These pre-treatment radiological features, namely high ASER-peri, high enhancement pattern, and well-defined tumor margins, have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.